21/07/2000
Following on from its successful placing and offer and admission to AIM on 24th March, 2000 ReGen Therapeutics Plc reports continuing progress with its development of Colostrinin, a potential treatment for Alzheimer’s Disease.
Three centres in Poland have now commenced late stage clinical trials. All three centres received favourable responses from their local Bio-Ethics Committees and almost one third of the intended study group have now commenced treatment. However, to speed up patient recruitment the Company has decided to extend the trial to further centres and negotiations are at an advanced stage.
The clinical trial protocol provides for the data to be reviewed by the Steering Committee after 42 patients have completed three treatment cycles. The Company expects to reach this point before the end of the year. This data will enable the Committee to determine whether to complete the study on a placebo controlled or open label basis. The Company will publish the Committee’s findings subsequently.
A significant milestone has now been achieved in the Company’s Intellectual Property Portfolio, having now filed a PCT application for some of the Peptide Structures that make up the Colostrinin complex. While no patent has yet been granted, the Company hopes that this new application, if granted, will extend the Company’s Intellectual Property position by protecting the structure of Colostrinin in all major markets.
Progress is also being made in identifying some of the steps that may allow for the commercial production of Colostrinin. Many of the key regulatory targets have now been identified and specific project work is being commissioned to address these issues.
Chairman Percy Lomax, comments that, “These statements show we are continuing to achieve progress in the development of our Company. We will continue to report progress on a regular basis”.